Xylaria

1. Dr. V. RAMESH
Assistant Professor & Head i/c,
Department of Botany, Vivekananda College,
(Residential & Autonomous – Gurukula Institute of Life Training)
Tiruvedakam West – 625 234.
Madurai.

3. REFERENCES
Kevin D. Hyde et al., (2019) The amazing potential of fungi: 50 ways we can exploit fungi
Industrially. Fungal Diversity, 97:1–136.
Luciana M. Elias et al., (2018) The potential of compounds isolated from Xylaria spp. as antifungal
agents against anthracnose. Brazilian Journal of Microbiology, 49: 840–847.
Tuan Noraida Tuan Hamzah et al., (2018) Diversity and Characterization of Endophytic Fungi Isolated
From the Tropical Mangrove Species, Rhizophora mucronata, and Identification of Potential Antagonists
Against the Soil-Borne Fungus, Fusarium solani. Frontiers in Microbiology, 9: 1-13
Rong Chen et al., (2018) Secondary Metabolites from the Endophytic Fungus Xylaria sp. hg1009.
Natural Products and Bioprospecting, 8:121–129.
Mohd Adnan et al., (2018) Formulation, evaluation and bioactive potential of Xylaria primorskensis
terpenoid nanoparticles from its major compound xylaranic acid. Scientific Reports, 8:1740 – 1752.
Ramesh et al., (2015) Novel Bioactive Wild Medicinal Mushroom—Xylaria sp. R006 (Ascomycetes)
against Multidrug Resistant Human Bacterial Pathogens and Human Cancer Cell Lines. International
Journal of Medicinal Mushrooms, 17(10): 1005–1017.

4. Why Xlaria spp.?
Xylaria is a large and the first described genus of the family Xylariaceae
They may be Lived as a Saprophytes or sometimes Parasitic or
Endophytes.
They may be found mostly on wood, sawdust, leaf, dung or soil.
It is a natural source of bioactive secondary metabolites like
Cytochalsins (Dagne et al., 1994), Xylaramides (Schneider et al., 1996),
Xanthones (Healy et al., 2004) and Griesofulvins (Park et al., 2005). etc.

5. X. gigantea
X. nigripesX. longipes
X. polymorpha
X.apiculata X. carpophila
X. cubensis X. curta
X. feejeensis X. filiformis
Xylaria digitata Xylaria persicaria
X. hypoxylon
Xylaria sp. Xylaria sp.
X. primorskensis
Diversity of Xylaria spp.
(Koyani et al., 2016) (Karun & Sridhar, 2015) (Adnan et al., 2017)

6. Xylarighan & Orthosporin
(Xylaria sp. hg1009)
Xylarinic acid (X. primorskensis)
Cytochalasin D
Xylaria sp. 214
Piliformic acid
Xylaria sp. 249
CHEMICAL DIVERSITY
Nigriterpene
(Elias et al., 2018)
(Chang et al., 2017)
(Chen et al., 2018)
(Adnan et al., 2017)

7. a b
c
NATURAL HABITATS
Xylaria curta (JF795289) Xylaria sp. (JF795290)
Xylaria sp. (KC405623)

8. Xylaria curta (JF795289) Xylaria sp. (JF795290)

9. Xylaria sp. (KC405623)
Morphology on PDA Fruiting bodies on PDB
Natural fruiting bodies Ascospores (100x)
Natural Habitat
Preparation of Extraction

10. Staphylococcus aureus (1-10) and Pseudomonas aeruginosa (1-8)
were obtained from Bose Clinical Laboratory, Madurai, Tamilnadu,
India.
Staphylococcus aureus Pseudomonas aeruginosa
HUMAN CANCER CELL LINES
A-549,
MCF-7
MDA-MB-231
CLINICAL STRAINS

11. 24 h
Bioactivities of Fraction E

12. nm
Abs
Absorption peak at 236 nm
indicates - alcohols, amines, halides,
ethers.
Absorption peak at 396 nm
indicates - chromophoric group.
UV spectrum
Wave number (cm-1)
Abs
The tentatively assigned peak at 3438 cm-1
indicates the presence of hydrogen bonding (OH
or NH).
The band around 2935 cm-1 is due to H-C-H
symmetric stretching.
The broad peak at 1699 cm-1 is due to C=O
stretching and the peaks at 1454, 1390-1228 &
1053 indicate C-C=C asymmetric, N-
H and C-O stretches.
IR spectrum

13. CONCLUSION
Present study revealed that the fruiting body extract of Xylaria sp.
(KC405623) had an effective broad spectrum antibacterial and cytotoxic
activity against drug resistant bacterial pathogens and human cancer
cell lines.
Xylaria sp. (KC405623) could be used as pharmaceutical substances
having diverse therapeutic applications once the nature of active
components will be elucidated.

14. Acknowledgement
Dr. Srigiridhar Kotamraju
Dr. C. Karunakaran
Dr. A . Rajendran

15. THANK YOU ALL